Johnson & Johnson

NYSE: JNJ
$154.52
-$0.02 (0.0%)
Closing Price on November 26, 2024

JNJ Articles

Here is a review and preview of how the model for Dow Jones industrial average could point to a baseline expectation of more than 7% gains in 2020.
The top analyst upgrades, downgrades and initiations for the final trading days of 2019 included Activision Blizzard, Amazon.com, Apple, Boeing, Eli Lilly, Johnson & Johnson, Lennar, Nio, Nvidia...
As of the most recently reported period, short sellers favored Microsoft, Pfizer and Intel above all other Dow stocks.
Thursday's top analyst upgrades, downgrades and initiations included Applied Materials, Barrick Gold, Best Buy, Blackstone, Boeing, Cisco Systems, Johnson & Johnson, KKR, McDonald's, Micron...
Tuesday's top analyst upgrades, downgrades and initiations included Alcoa, Bed Bath & Beyond, Boeing, CenturyLink, DuPont, FedEx, Groupon, Johnson & Johnson, Micron Technology, Microsoft and...
One theme that investors love in good times and in bad is dividend investing. One strategy that has been around for years is known as the Dogs of the Dow.
Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some. The biotechnology sector is pushing near all-time highs, and a few of...
Wednesday's top analyst upgrades, downgrades and initiations include Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, Johnson & Johnson, Replimune, Schlumberger and Transocean.
Despite the never-ending election cycle, there actually is a clear path for the Dow to hit 30,000 as soon as early 2020, if only a few things come to fruition. There does not even have to be a big...
With markets at all-time highs, it's important to consider the winners and losers. In this case, many stocks in the Dow are still holding the index back from even stronger gains.
Goldman Sachs may have the best strategy for investors for 2020. Here are five stocks that look like great ideas now for investors looking to mold such a plan.
Johnson & Johnson has found itself involved in more controversy than the company would prefer to see. But it seems that not even bad news lasts forever.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Wednesday's top analyst upgrades, downgrades and initiations included Adobe, Alibaba, Amazon.com, AT&T, Comcast, Delphi Technologies, DocuSign, Johnson & Johnson, JPMorgan, T-Mobile, Verizon...
Johnson & Johnson reported better than expected quarterly results before the markets opened on Tuesday.